Applications and approvals for new molecular entities (NMEs) in the United States continue to fall ...
... while it continues to dominate R&D spending and total pharmaceutical sales.
- Ken Kostel
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!